Search results
In a 'gold rush' for treating bowel disease, AbbVie clears one more stage
Crain s Chicago Business· 4 days agoWith the arrival of biosimilar competition for its blockbuster drug Humira, AbbVie has said much of its sales growth potential lies with these two anti-inflammatories. In April, the North Chicago ...
Top 5 Small-Cap Biotechnology Stocks for a Stable Portfolio
Zacks via Yahoo Finance· 3 days agoARQT is focused on developing and commercializing treatments for unmet needs in immune-mediated...
JD Supra: AbbVie Files Notice of Data Breach Impacting the Health Information of Tens of Thousands...
JD Supra· 1 day agoOn May 22, 2024, AbbVie, Inc. filed a notice of data breach with the Attorney General of Texas after discovering that confidential information that had been entrusted to the company was subject ...
U.S. FDA Approves SKYRIZI® (risankizumab-rzaa) for Ulcerative Colitis, Expanding AbbVie's Portfolio...
Morningstar· 5 days agoApproval supported by two Phase 3 clinical trials that evaluated SKYRIZI® for the treatment of moderate to severe ulcerative colitis: a 12-week induction study, INSPIRE,1 and a 52-week maintenance study, COMMAND2Data showed that clinical remission,
Here Comes the Sun: We Are Your Summer Skincare Experts
Lancaster Online· 4 days agoSummer is finally here and, for most of us, that means more time in the sun - whether it’s relaxing...
Johnson & Johnson (NYSE:JNJ) is Adirondack Trust Co.’s 10th Largest Position
ETF DAILY NEWS· 5 days agoAdirondack Trust Co. cut its position in shares of Johnson & Johnson (NYSE:JNJ – Free Report) by 3.4% in the fourth quarter, according to the company in its most recent disclosure with the Securities ...
TREMFYA® (guselkumab) studies underscore its potential to be the only IL-23 inhibitor to offer both...
Morningstar· 4 days agoJohnson & Johnson (NYSE: JNJ) today announced positive topline results from the pivotal Phase 3 GRAVITI investigational study of TREMFYA® (guselkumab) subcutaneous (SC) induction therapy in ...
Hollings Renton Sells 1,950 Shares of AnaptysBio, Inc. (NASDAQ:ANAB) Stock
ETF DAILY NEWS· 5 days agoAnaptysBio, Inc. (NASDAQ:ANAB – Get Free Report) Director Hollings Renton sold 1,950 shares of the business’s stock in a transaction dated Tuesday, June 18th. The stock was sold at an average ...
Putting the brakes on chronic inflammation | Cornell Chronicle
Cornell News Service· 7 days agoThe immune system has many pathways to protect the body from infection, but sometimes an overactive...
This Rx-Only Wound Cream Is Like Your Daily Moisturizer on Steroids
Robb Report via Yahoo News· 5 days agoShe added that it can also be prescribed to manage chronic sensitive skin conditions including...